Background Opicapone (OPC), a novel once-daily peripheral COMT inhibitor, has shown to be safe and effective in reducing OFF-time in Parkinson’s disease (PD) patients with motor fluctuations.
Objective To evaluate the efficacy of OPC in levodopa-treated PD patients with motor fluctuations and subdivided by their baseline OFF-time.
Methods BIPARK-I was a multinational, multicentre, double-blind, 14–15-week, placebo and active-controlled study to evaluate the efficacy of OPC in PD patients with end-of-dose motor fluctuations. This post-hoc subgroup analysis investigated efficacy of OPC 50 mg and entacapone (ENT), in levodopa-treated PD patients who were subdivided by baseline OFF-time (>90 mins and every additional 30 mins interval up to an interval with minimum sample size of 40 patients per active arm).
Results Subjects with higher baseline OFF-times had a greater response under both OPC 50 mg and ENT with an average difference of -26.6 mins OFF-time reduction favouring OPC 50 mg. The estimated difference increased with increasing baseline OFF-time, reaching statistically significance (p<0.05) for subjects with >390 mins baseline OFF-time.
Conclusion Higher baseline OFF-time correlated with greater response for both OPC 50 mg and ENT. OPC 50 mg presented a greater OFF-time reduction than ENT for all subgroup intervals, reaching statistically significance for subjects with >390 mins baseline OFF-time.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.